###begin article-title 0
###xml 112 116 <span type="species:ncbi:10090">Mice</span>
Diverse Hematological Malignancies Including Hodgkin-Like Lymphomas Develop in Chimeric MHC Class II Transgenic Mice
###end article-title 0
###begin p 1
Conceived and designed the experiments: SHR LQM DJS. Performed the experiments: SHR GH SK JM. Analyzed the data: SHR GH SK JM LQM DJS. Wrote the paper: SHR GH DJS.
###end p 1
###begin p 2
Current address: Roche Diagnostics, Pathology and Tissue Biomarker, Penzberg, Germany
###end p 2
###begin p 3
Current address: Lovelace Respiratory Research Institute, Albuquerque, New Mexico, United States of America
###end p 3
###begin p 4
Current address: Institute of Pathology, University of Tubingen, Tubingen, Germany
###end p 4
###begin p 5
###xml 806 807 806 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
###xml 578 583 <span type="species:ncbi:9606">human</span>
###xml 904 908 <span type="species:ncbi:10090">mice</span>
###xml 1094 1099 <span type="species:ncbi:9606">human</span>
###xml 1425 1428 <span type="species:ncbi:9606">man</span>
A chimeric HLA-DR4-H2-E (DR4) homozygous transgenic mouse line spontaneously develops diverse hematological malignancies with high frequency (70%). The majority of malignancies were distributed equally between T and B cell neoplasms and included lymphoblastic T cell lymphoma (LTCL), lymphoblastic B cell lymphoma (LBCL), diffuse large B cell lymphoma (DLBCL), the histiocyte/T cell rich variant of DLBCL (DLBCL-HA/T cell rich DLBCL), splenic marginal zone lymphoma (SMZL), follicular B cell lymphoma (FBL) and plasmacytoma (PCT). Most of these neoplasms were highly similar to human diseases. Also, some non-lymphoid malignancies such as acute myeloid leukemia (AML) and histiocytic sarcoma were found. Interestingly, composite lymphomas, including Hodgkin-like lymphomas, were also detected that had CD30+ Hodgkin/Reed-Sternberg (H/RS)-like cells, representing a tumor type not previously described in mice. Analysis of microdissected H/RS-like cells revealed their origin as germinal center B cells bearing somatic hypermutations and, in some instances, crippled mutations, as described for human Hodgkin lymphoma (HL). Transgene integration in an oncogene was excluded as an exclusive driving force of tumorigenesis and age-related lymphoma development suggests a multi-step process. Thus, this DR4 line is a useful model to investigate common molecular mechanisms that may contribute to important neoplastic diseases in man.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 95 101 <span type="species:ncbi:9606">humans</span>
###xml 107 112 <span type="species:ncbi:10090">mouse</span>
###xml 221 226 <span type="species:ncbi:10090">mouse</span>
###xml 237 242 <span type="species:ncbi:9606">human</span>
The similarities between genomes and genetic pathways underlying tumor development in mice and humans make mouse models ideal for the study of cancer pathogenesis. Numerous inbred, virus-induced or genetically-engineered mouse models of human malignancy have been developed in the past to gain insight into mechanisms of tumorigenesis.
###end p 7
###begin p 8
###xml 156 159 156 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Kogan1">[1]</xref>
###xml 161 164 161 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Morse1">[2]</xref>
###xml 599 602 599 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Janz1">[3]</xref>
###xml 641 644 641 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Jardin1">[4]</xref>
###xml 691 694 691 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Hoogervorst1">[5]</xref>
###xml 775 778 775 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Lin1">[6]</xref>
###xml 807 810 807 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Mikkers1">[7]</xref>
###xml 859 862 859 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Eriksson1">[8]</xref>
###xml 999 1002 999 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Park1">[9]</xref>
###xml 1014 1018 1014 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Deshpande1">[10]</xref>
###xml 1077 1081 1077 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Largaespada1">[11]</xref>
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
###xml 271 276 <span type="species:ncbi:9606">human</span>
###xml 505 510 <span type="species:ncbi:9606">human</span>
###xml 783 786 <span type="species:ncbi:8790">Emu</span>
###xml 791 806 <span type="species:ncbi:10090">transgenic mice</span>
###xml 838 843 <span type="species:ncbi:10090">mouse</span>
###xml 1046 1069 <span type="species:ncbi:11786">murine leukemia viruses</span>
###xml 1071 1075 <span type="species:ncbi:11786">MuLV</span>
###xml 1207 1212 <span type="species:ncbi:10090">mouse</span>
Several mouse models exist for hematopoietic malignancies which correspond to distinct tumor entities, including B or T cell lymphomas or myeloid leukemias [1], [2]. A number of these models rely on tumor transplantation, which poorly reflects the process that occurs in human malignancy, particularly with respect to multi-step events. This can be partially rectified with the use of spontaneous tumor models that are created by introducing known genes, such as chromosomal translocations which occur in human tumors. As examples, B cell malignancies were induced by translocation of the myc-locus [3], knock-in of the proto-oncogene Bcl-6 [4] or knock-out of the p53 tumor suppressor gene [5]. Spontaneous T cell malignancies were generated by expression of mutated Notch1 [6], in Emu-myc transgenic mice [7] or by induction of Moloney mouse leukemia virus [8]. Furthermore, leukemic malignancies were forced through integration of fusion-genes that mimic chromosomal alterations, such as myc-IgH [9], CALM/AF10 [10] or through introduction of murine leukemia viruses (MuLV) [11]. These various models share the characteristic that principally one distinct lineage-specific tumor-type is detected in each mouse strain.
###end p 8
###begin p 9
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Ito1">[12]</xref>
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
###xml 503 508 <span type="species:ncbi:9606">human</span>
###xml 549 554 <span type="species:ncbi:10090">mouse</span>
###xml 726 731 <span type="species:ncbi:9606">human</span>
We discovered that an established MHC class II transgenic (tg) mouse line, developed by Ito and coworkers as a model for autoimmunity [12] developed spontaneous tumors starting around eight months of age. Extensive cellular and molecular characterization revealed that widely diverse hematopoietic neoplasms occur in these mice, which arise from different lineages and represent different stages of lymphocyte development. Surprisingly, many of these neoplasms had phenotypes that are characteristic of human hematological diseases. Therefore, this mouse line provides a unique tumor model that broadly extends the possibilities to study potential multistep-processes involved in tumorigenesis in vivo, with high relevance to human hematological malignancy.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
###xml 61 65 <span type="species:ncbi:10090">Mice</span>
Various Hematological Malignancies Develop in DR4-H2E and F1 Mice
###end title 11
###begin p 12
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 283 284 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 283 284 272 273 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>d</sup></bold>
###xml 296 297 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 296 297 282 283 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sup>d</sup></bold>
###xml 568 572 554 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Ito1">[12]</xref>
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 82 87 <span type="species:ncbi:10090">mouse</span>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 192 197 <span type="species:ncbi:9606">human</span>
###xml 255 260 <span type="species:ncbi:10090">mouse</span>
###xml 409 413 <span type="species:ncbi:10090">mice</span>
###xml 477 482 <span type="species:ncbi:10090">mouse</span>
###xml 525 529 <span type="species:ncbi:10090">mice</span>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
###xml 604 608 <span type="species:ncbi:10090">mice</span>
###xml 736 741 <span type="species:ncbi:9606">human</span>
###xml 925 931 <span type="species:ncbi:10090">murine</span>
###xml 987 992 <span type="species:ncbi:10090">mouse</span>
The previously published DR4-H2E transgenic mouse line expresses a chimeric human-mouse MHC class II gene (HLA-DR4/H2Ed). DR4-H2E mice express MHC class II chimeric molecules, composed of the human DR4alpha and DR4beta peptide binding-domains, coupled to mouse MHC class II (H2Ealphad and H2Ebetad) constant domains, respectively. One DR4-H2E transgenic founder line was backcrossed to MHC class II-deficient mice (C2d-C57BL/6 background) to eliminate expression of endogenous mouse class II molecules and DR4-H2E homozygous mice (hereafter DR4 mice) were established [12]. All offspring of DR4 parental mice expressed chimeric class II molecules on splenic B cells but not T cells, as depicted using a monoclonal antibody specific for human DRB1*0401 molecules (data not shown). These results confirmed homozygosity of the DR4-H2E transgene in the parental line. Cellular interactions were preserved with CD4 coreceptors on murine T cells by retaining the alpha-2 and beta-2 domains of mouse MHC class II in the chimeric protein.
###end p 12
###begin p 13
###xml 319 320 319 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 845 854 845 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g001">Figure 1A</xref>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 156 162 <span type="species:ncbi:10090">murine</span>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 289 293 <span type="species:ncbi:10090">mice</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 604 608 <span type="species:ncbi:10090">mice</span>
###xml 760 764 <span type="species:ncbi:10090">mice</span>
Our new finding is that DR4 mice spontaneously develop hematopoietic malignancies at high frequency (69.7%). To explore the role of DR4 homozygosity versus murine H2 class II deficiency on tumor occurrence, DR4 animals were crossed with wildtype C57BL/6 mice, yielding DR4 heterozygous F1 mice which carry one normal H2b MHC haplotype and thereby are no longer H2 class II deficient. Tumor development in F1 mice would imply a dominant oncogenic effect associated with DR4-H2E transgene heterozygosity and only a minor contribution of H2 class II deficiency to tumorigenesis. Indeed, DR4 heterozygous F1 mice also developed different types of lymphoma with high frequency, as described in more detail below. Tumor appearance was assessed in 132 DR4 and 125 F1 mice, yielding frequencies of 69.7% (92 of 132) and 52.8% (66 of 125), respectively (Figure 1A).
###end p 13
###begin title 14
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Survival plot and comparison of neoplasm distribution between DR4 and F1 mice.
###end title 14
###begin p 15
###xml 38 42 <span type="species:ncbi:10090">mice</span>
###xml 95 99 <span type="species:ncbi:10090">mice</span>
###xml 186 191 <span type="species:ncbi:10090">mouse</span>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 776 780 <span type="species:ncbi:10090">mice</span>
###xml 845 849 <span type="species:ncbi:10090">mice</span>
###xml 968 972 <span type="species:ncbi:10090">mice</span>
###xml 990 994 <span type="species:ncbi:10090">mice</span>
###xml 1001 1006 <span type="species:ncbi:10090">mouse</span>
(A) Tumor-free survival of DR4 and F1 mice within 24 months shown by the frequency of diseased mice in DR4 and F1-strains in relation to their age. Each symbol represents one individual mouse. Disease appeared at 8.5 months of age in DR4 mice whereas in the heterozygous F1 generation tumors could be observed at 7 months. Around 70% of DR4 mice and 53% of F1 mice developed lymphomas, 30% and 47% survived, respectively. Results were subjected to statistical analysis using GraphPad Prism v5.0 software (GraphPad Software, San Diego California USA, ). Survival curves were analyzed using the Kaplan-Meier method and were compared with the log-rank test and by median survival. Kaplan-Meier survival curve shows significantly decreased median survival of DR4 compared with F1 mice. Median survival of DR4 was 16.5 months versus 15 months for F1-mice (log-rank test, p = 0.0159). Data represent DR4, n = 131; F1, n = 125. (B) Distribution of different neoplasms in DR4 mice compared with F1 mice. Both mouse strains developed lymphoid tumors (T and B cell neoplasms) with a similar frequency of around 75%.
###end p 15
###begin p 16
###xml 135 138 135 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Kogan1">[1]</xref>
###xml 140 143 140 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Morse1">[2]</xref>
###xml 426 435 426 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g001">Figure 1B</xref>
###xml 564 571 564 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008539-t001">Table 1</xref>
###xml 779 788 779 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s001">Figure S1</xref>
###xml 1100 1104 1100 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Bellan1">[13]</xref>
###xml 1144 1148 1144 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Brauninger1">[14]</xref>
###xml 1161 1165 1161 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Zettl1">[15]</xref>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 558 562 <span type="species:ncbi:10090">mice</span>
###xml 1199 1202 <span type="species:ncbi:9606">man</span>
Tumors were classified histologically according to the Bethesda Proposal for lymphoid and non-lymphoid hematopoietic neoplasms in mice [1], [2]. Expression of lineage-specific markers was assessed by immunohistochemistry to support histopathology and was confirmed in many cases by multi-parameter flow cytometry of thymic or splenic single cell suspensions. The hematologic neoplasms arising in DR4 and F1 mice were similar (Figure 1B). Most malignancies were of lymphoid origin with 35.9% (33 of 92) T cell tumors and 39.1% (36 of 92) B cell tumors in DR4 mice (Table 1). Several cases of AML (4.3%) and two cases of histiocytic sarcoma were also observed. Furthermore, 16.3% of animals had composite tumors with mixtures of B cell and T cell tumors or B cell tumors with AML (Figure S1). Some composite tumors contained mononucleated Hodgkin-like or multinucleated RS-like cells (see below). These lymphomas accounted for 10.9% of malignancies and were generally a mixture of T cell/histiocytic rich variant of DLBCL and LTCL. A similar occurrence of HL in composite lymphomas appearing with LBCL [13], with the T cell rich variant of DLBCL [14] or with MZL [15] has been described previously in man.
###end p 16
###begin title 17
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Distribution of neoplasms in transgenic DR4-mice.
###end title 17
###begin title 18
Characterization of T Cell Neoplasms
###end title 18
###begin p 19
###xml 127 136 127 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g002">Figure 2A</xref>
###xml 213 222 213 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g002">Figure 2B</xref>
###xml 564 575 564 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g002">Figure 2C&#8211;D</xref>
###xml 660 661 660 661 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 679 688 679 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g002">Figure 2E</xref>
###xml 717 718 717 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 721 722 721 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 732 741 732 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g002">Figure 2F</xref>
###xml 865 869 865 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Brunning1">[16]</xref>
###xml 4 10 <span type="species:ncbi:10090">murine</span>
###xml 832 836 <span type="species:ncbi:10090">mice</span>
###xml 858 864 <span type="species:ncbi:9606">humans</span>
###xml 903 908 <span type="species:ncbi:9606">human</span>
All murine T cell neoplasms were diagnosed as lymphoblastic T cell lymphomas (LTCL). These had a typical "starry sky" pattern (Figure 2A) with massive infiltration of lymph nodes, spleen, lung, kidneys and liver (Figure 2B). These neoplasms represented a monotonous population of medium-sized cells, with scant cytoplasm and blastic chromatin with one to two small nucleoli, intermingled with abundant histiocytes with tingible bodies. Immunohistochemical analysis revealed that neoplastic cells were terminal deoxynucleotidyl transferase (Tdt)- and CD3-positive (Figure 2C-D) but negative for the B cell marker, B220. LTCL were either single-positive (SP) CD4+ or CD8+ T cells (Figure 2E) or double-positive (DP) CD4+CD8+ T cells (Figure 2F), as shown by flow cytometry. Single-positive LTCL represent a common type of lymphoma in mice that is not found in humans [16], whereas DP LTCL have recognized human counterparts.
###end p 19
###begin title 20
Lymphoblastic T cell lymphoma (LTCL).
###end title 20
###begin p 21
(A-D). Histology and immunohistochemistry of LTCL (all bars equal 50 microm). (A) LTCL consists of uniform cells with scant cytoplasm showing high mitotic and apoptotic rates and the typical starry sky pattern (hematoxylin & eosin, H&E). (B) CD3+ infiltrates in the liver. (C). Tumor cells are positively stained for Tdt (terminal deoxynucleotidyl transferase) and (D) CD3. (E-F) Flow cytometry analysis of T cell receptor Vbeta-repertoire on tumor-bearing spleen samples. (E) Monoclonal single positive (SP) CD4+ LTCL. Dot plots - top: gated on CD3+B220- cells: CD4 versus CD8, middle: gated on SP CD4+ T cells showing the Vbeta8.2+ tumor cell population and an irrelevant Vbeta-chain (Vbeta6); bottom: gated on DP CD4/Vbeta8.2 as shown in histogram all other Vbeta-families were negative. (F) Monoclonal precursor LTCL gated on CD3+ B220- cells: top: CD4 versus CD8, middle: monoclonal DP CD4+CD8+ tumor cells expressing two Vbeta-chains (Vbeta7&Vbeta10), bottom: gated on DP Vbeta7/Vbeta10 tumor cells, as shown in histogram all other Vbeta-families were not expressed. (G) Lymphocytes were stained as for FACS-analyses; top: Vbeta7-PE in red, middle: Vbeta10-FITC in green, bottom: merged image showing co-localization of Vbeta7-PE and Vbeta10-FITC as dual T cell receptors on splenic tumor cells with deconvolution microscopy. All bars equal 5 microm.
###end p 21
###begin p 22
###xml 140 148 140 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s002">Table S1</xref>
###xml 153 161 153 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s003">Table S2</xref>
###xml 267 271 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Pannetier1">[17]</xref>
###xml 1524 1533 1506 1515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g002">Figure 2E</xref>
###xml 1559 1560 1541 1542 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1727 1735 1706 1714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s002">Table S1</xref>
###xml 1822 1830 1798 1806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s002">Table S1</xref>
###xml 1865 1866 1841 1842 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1869 1870 1845 1846 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1956 1965 1929 1938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g002">Figure 2F</xref>
###xml 2062 2071 2032 2041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g002">Figure 2G</xref>
###xml 2162 2166 2129 2133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Padovan1">[18]</xref>
###xml 2310 2314 2277 2281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Simpson1">[19]</xref>
###xml 2469 2477 2436 2444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s002">Table S1</xref>
###xml 2482 2490 2449 2457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s003">Table S2</xref>
###xml 134 138 <span type="species:ncbi:10090">mice</span>
###xml 1032 1037 <span type="species:ncbi:10090">Mouse</span>
###xml 1715 1720 <span type="species:ncbi:10090">Mouse</span>
###xml 1809 1814 <span type="species:ncbi:10090">Mouse</span>
###xml 2080 2085 <span type="species:ncbi:9606">human</span>
###xml 2203 2208 <span type="species:ncbi:10090">mouse</span>
###xml 2463 2467 <span type="species:ncbi:10090">mice</span>
Molecular analysis of T cell receptor (TCR) usage indicated a monoclonal origin of all T cell tumors that were examined in DR4 and F1 mice (Table S1 and Table S2). To assess clonality, we used an RT-PCR-based TCR Vbeta-repertoire analysis detecting 21 Vbeta-families [17]. All detected amplicons were sequenced and evaluated for standard characteristics of functionally rearranged Vbeta-chains: in-frame rearrangements, lack of stop-codons, conserved cysteine at position 104 and the conserved Phe-Gly-X-Gly-motive (IMGT-Database). Where possible, molecular characterization of LTCL was supported by TCR surface phenotyping of neoplastic cells using corresponding Vbeta-specific monoclonal antibodies. The frequency of tumor cells in starting materials of LTCL varied from 36-99%, perhaps reflecting the status of tumor progression in the examined animals (data not shown). Despite cellular heterogeneity, the TCR Vbeta-repertoires of all tumors were restricted to a few prominent amplicons. Furthermore, in all cases but one (i.e. Mouse ID-10), only a single amplicon sequence displayed the characteristics of a functional Vbeta-chain. In several tumors, a second amplicon revealed a "non-functional" rearranged TCR sequence. The presence of some contaminating normal T cells was evident in the background of electropherograms, but these sequences were below a signal threshold that allowed individual sequences to be defined, suggesting they were composed of mixtures of different sequences (data not shown). As examples, Figure 2E shows a monoclonal SP CD4+ tumor expressing a Vbeta8.2-receptor representing 98% of splenic CD4 T cells. The surface phenotype confirmed the TCR sequence designation of this tumor (Mouse ID-8, Table S1). In the second case, two Vbeta-receptor sequences were found by RT-PCR (Mouse ID-10, Table S1) and surface phenotyping of DP CD4+CD8+ tumor cells showed staining with corresponding Vbeta-specific monoclonal antibodies (Figure 2F). Confocal microscopy corroborated that both Vbeta-chains were colocalized on individual cells (Figure 2G). While human T cells naturally expressing two Vbeta-chains have been reported previously [18], this has not been seen with normal mouse T cells but has been observed for T cells from TCR transgenic animals that co-express endogenous TCR [19]. Based on combined molecular and cellular analyses, the results indicated a monoclonal origin of all T cell tumors that were examined in DR4 and F1 mice (Table S1 and Table S2).
###end p 22
###begin title 23
Characterization of B Cell Neoplasms
###end title 23
###begin p 24
###xml 155 166 151 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3A+B</xref>
###xml 427 436 423 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3B</xref>
###xml 493 504 489 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3C+D</xref>
###xml 799 810 795 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3E+F</xref>
###xml 882 886 878 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Lim1">[20]</xref>
###xml 928 939 924 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3G+I</xref>
###xml 1310 1319 1306 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3H</xref>
###xml 1350 1359 1346 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3I</xref>
###xml 1537 1546 1533 1542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3J</xref>
###xml 1735 1739 1731 1735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Kunder1">[21]</xref>
###xml 1782 1793 1778 1789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3K+L</xref>
###xml 1963 1974 1959 1970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3M&#8211;O</xref>
###xml 2156 2165 2152 2161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3N</xref>
###xml 2186 2195 2182 2191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g003">Figure 3O</xref>
###xml 878 881 <span type="species:ncbi:9606">man</span>
###xml 1392 1397 <span type="species:ncbi:9606">human</span>
###xml 1428 1434 <span type="species:ncbi:10090">murine</span>
###xml 1665 1670 <span type="species:ncbi:9606">human</span>
###xml 1702 1708 <span type="species:ncbi:10090">murine</span>
###xml 2225 2230 <span type="species:ncbi:9606">human</span>
The B cell neoplasms were morphologically very heterogeneous but all were positive for CD79a (Igalpha) and/or B220. B cell lymphoblastic lymphomas (LBCL) (Figure 3A+B) were characterized by medium-sized cells with scant cytoplasm, blastic chromatic and one prominent nucleolus. These tumors showed massive infiltration of different organs, starry sky patterns and numerous mitotic figures. Tumor cells were positive for CD79a (Figure 3B), B220 and Tdt. Diffuse large B-cell lymphomas (DLBCL) (Figure 3C+D) had medium to large centroblastic and immunoblastic cells with pale cytoplasm, round vesicular nuclei and prominent nucleoli. Many DLBCL showed conspicuous infiltration with reactive CD3-positive T cells. Half of the DLBCL belonged to the morphological histiocyte-associated variant DLBCL-HA (Figure 3E+F), which corresponds to T cell/histiocytic rich variant of DLBCL in man [20]. Splenic marginal zone lymphomas (SMZL) (Figure 3G+I) were composed of monomorphic, pale tumor cells with regular nuclei and abundant cytoplasm. Early cases were restricted to the marginal zone and advanced cases showed invasion into the red pulp of the spleen or rarely into other organs. Their low proliferative activity was reflected by a low number of mitotic figures (data not shown). SMZL were always CD79a positive (Figure 3H) and often negative for B220 (Figure 3I). The similarity of SMZL to its human counterpart is very high. The murine follicular B cell lymphoma (FBL) was characterized by a mixture of centrocytes and centroblast cells (Figure 3J). These tumors were usually B220 positive and negative for Bcl2 (data not shown). Although morphologically similar to human lymphomas, the pathogenesis of murine FBL seems to be different [21]. Well-differentiated plasmacytomas (PCT) (Figure 3K+L) consisted of plasma cells in different stages of maturation, which were positive for CD138 and CD79a. One case of B natural killer cell lymphoma (BNKL) was also found (Figure 3M-O). It consisted of large pale cytoplasm-rich cells, often with indented nuclei and prominent nucleoli. Tumor cells appeared as mature large B cells with surface expression of CD79a (Figure 3N) and NK1.1 in FACS (Figure 3O). This tumor lacks any known human counterpart.
###end p 24
###begin title 25
B cell neoplasms.
###end title 25
###begin p 26
(A-K) Histology (H&E) and immunohistochemistry (all bars equal 50 microm). (A) Lymphoblastic B cell lymphoma (LBCL) shows blastic nuclei with prominent nucleoli and numerous mitotic figures. (B) Staining for CD79a+. (C) Diffuse large B cell lymphoma (DLBCL) consists of immunoblastic and centroblastic cells and is (D) CD79a+. (E) The histiocyte-associated variant (DLBCL-HA) shows participation of many histiocytes and granulocytes. (F) B220+ DLBCL-HA. (G-I) The splenic marginal zone lymphoma (SMZL) is usually (H) CD79a+ but (I) B220-. (J) H&E of follicular B cell lymphoma. (K-L) Well-differentiated plasmacytomas display (L) CD79+ plasma cells. (M-O) The cellular phenotype of the B natural killer cell lymphoma (BNKL) is confirmed by (N) positively stained CD79a B cells and (O) DP B220/NK1.1 cells in FACS.
###end p 26
###begin p 27
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 178 179 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 213 214 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 216 217 216 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 222 223 222 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 275 276 275 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 279 280 279 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 283 291 283 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s004">Table S3</xref>
###xml 299 307 299 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s008">Table S7</xref>
###xml 1292 1296 1292 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Lefranc1">[22]</xref>
###xml 1874 1882 1874 1882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s004">Table S3</xref>
###xml 1887 1895 1887 1895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s005">Table S4</xref>
###xml 148 153 <span type="species:ncbi:10090">Mouse</span>
###xml 195 200 <span type="species:ncbi:10090">Mouse</span>
###xml 246 251 <span type="species:ncbi:10090">Mouse</span>
FACS analysis confirmed a mature (B220+IgM+IgD+) phenotype of most B cell tumors, except LBCL. A few lymphomas had phenotypes of small pre-B cells (Mouse-ID 96,124; B220+Ig-CD117-), pro B-cells (Mouse-ID 109; B220+Ig-CD117+) or immature B cells (Mouse-ID 48,111,129; B220+IgM+IgD-) (Table S3 and/or Table S7). To determine clonality, RT-PCR analysis was made with immunoglobulin heavy chain (IgH)-specific primers for variable (V) and joining (J)-regions. Clonality was identified by sequence homogeneity of the amplified IgH fragments. Since whole spleen samples were used, a low background of contaminating sequences from normal B cells was observed but these mixed signals were below the threshold allowing individual sequence determination (data not shown). Sequences were considered to be monoclonal and functional if they were in-frame, had no stop-codons, a conserved cysteine at position 104 (IMGT-Database) and a Trp-Gly-X-Gly-motive similar to TCR analysis. Results indicated monoclonality in 80.6% of DR4 tumors and 78.6% of F1 tumors. In the remaining samples, the VDJ-junctions were not discernable as they consisted of multiple sequences, indicating that these tumors were likely to be oligoclonal. Further analysis of sequence data in comparison to reported germline sequences [22] was performed to search for mutations (silent or replacement mutations) in the framework regions FR1-FR3 and the complementarity determining regions CDR1-CDR3. The presence of mutations in FR1-FR3 and CDR1-CDR2, in addition to mutations in the CDR3-regions of VDJ-junctions, would indicate that tumor cells originated from mature, activated B cells of germinal centers with ongoing somatic hypermutations (SHM). Thirty percent of the examined DR4 B cell tumors (9 of 30) but only 14% of F1 tumors (2 of 14) showed mutations in the CDR3-regions of amplified IgH-rearrangements (Table S3 and Table S4) (data for mutations in FR1-3 and CDR1-2 not shown).
###end p 27
###begin title 28
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
CD30+ Hodgkin/Reed Sternberg-Like Cells of B Cell Origin
###end title 28
###begin p 29
###xml 175 186 175 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g004">Figure 4A&#8211;H</xref>
###xml 465 476 465 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g004">Figure 4I&#8211;L</xref>
###xml 490 501 490 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g004">Figure 4M&#8211;P</xref>
###xml 101 106 <span type="species:ncbi:9606">human</span>
###xml 359 364 <span type="species:ncbi:9606">Human</span>
###xml 427 433 <span type="species:ncbi:10090">murine</span>
###xml 574 580 <span type="species:ncbi:10090">murine</span>
###xml 746 751 <span type="species:ncbi:9606">human</span>
###xml 777 783 <span type="species:ncbi:10090">murine</span>
###xml 810 814 <span type="species:ncbi:10090">mice</span>
Unusual cells were found in the majority of composite lymphomas that were morphologically similar to human multinucleated Reed Sternberg cells or mononucleated Hodgkin cells (Figure 4A-H). These were designated as H/RS-like cells. A polymorphic infiltrate of B and T cells as well as histiocytes and plasma cells was detected surrounding the H/RS-like cells. Human H/RS cells are known to express CD30 molecules. Concordantly, murine H/RS-like cells in lymph node (Figure 4I-L) and spleen (Figure 4M-P) were also CD30 positive. We therefore aimed to determine whether these murine H/RS-like cells were of B cell origin and if characteristic mutations could be found in their IgH sequences. Such findings would further support their similarity to human HL. The B cell origin of murine H/RS-like cells from five mice was assessed using RT-PCR analysis of laser-assisted microdissected pools of 8-10 cells for each splenic tumor. Pooling of the cells was required to obtain adequate RNA from cells isolated from cryopreserved H&E sections that were identified without staining of specific markers but rather through morphologic distinction of H/RS-like cells. Sequence analysis was performed as described for B cell tumors above. Contaminating material from neighbouring normal B cells, if present, was below the threshold of detection in electropherograms.
###end p 29
###begin title 30
H/RS-like cells in composite lymphomas.
###end title 30
###begin p 31
###xml 611 615 <span type="species:ncbi:10090">mice</span>
(A-P+R-T) Histology and immunohistochemistry of Hodgkin-like lymphoma samples in composite compartments, surrounded by activated B and T cells as well as histiocytes. (A-H). H&E staining of (A-D) lymph node and (E-H) spleen sections containing Hodgkin/Reed-Sternberg (H/RS)-like cells (in white boxes). Magnification of characteristic (D+H) giant mononucleated Hodgkin-like and (B+F) multinucleated RS-like cells. (K+L & O+P) CD30+ Hodgkin-like and (I+J & M+N) RS-like cells in (I-L) lymph node and (M-P) spleen sections. (Q) CDR3-region of IgH-transcripts of microdissected H/RS-like cells from five different mice. (R-T) Immunohistochemistry of either B220 positive or negative (R) Hodgkin-like and (S) RS-like cells surrounded by (T) rosettes of CD3+ T cells. All bars equal 50 microm.
###end p 31
###begin p 32
###xml 383 392 383 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g004">Figure 4Q</xref>
###xml 613 617 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Kanzler1">[23]</xref>
###xml 619 623 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Kuppers1">[24]</xref>
###xml 829 837 829 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s006">Table S5</xref>
###xml 842 850 842 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s007">Table S6</xref>
###xml 596 601 <span type="species:ncbi:9606">human</span>
###xml 822 827 <span type="species:ncbi:10090">mouse</span>
Presence of IgH rearrangements showed that four tumors were indeed derived from B cells. Furthermore, amplicon sequence analysis and comparison with germline sequences (IMGT-Database) demonstrated the presence of mutations in the FR1-FR3 and CDR1-CDR3 regions of the specific amplicons, reflecting the occurrence of somatic hypermutation that occurs in germinal center (GC) B cells (Figure 4Q and data not shown). Interestingly, in addition to mutations in FR1-FR3 and CDR1-2 regions, two sequences displayed deleterious "crippling" mutations in their CDR3 regions, as has been reported for some human H/RS-cells [23], [24]. Based on IgH sequence comparisons of nucleotides inserted within the VD and DJ junctions, a clonal relationship was excluded between H/RS-like cells and tumor cells of DLBCL-HA or SMZL in the same mouse (Table S5 and Table S6).
###end p 32
###begin p 33
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 122 133 122 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g004">Figure 4R&#8211;T</xref>
###xml 280 288 280 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s008">Table S7</xref>
###xml 290 297 290 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008539.s009">File S1</xref>
###xml 417 421 417 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Schwering1">[25]</xref>
###xml 400 405 <span type="species:ncbi:9606">human</span>
###xml 577 583 <span type="species:ncbi:9606">humans</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
Individual H/RS-like cells were positive or negative for B220 and were often surrounded by CD3+ reactive T cell rosettes (Figure 4R-T). Surface phenotypes of H/RS-like cells in composite tumors were unclear due to low frequencies (2-5%) of accompanying non-H/RS-like tumor cells (Table S7; File S1). Loss of expression of B cell markers, such as B220 on H/RS-like cells, was previously described for human H/RS cells [25]. In total, the characterization of these unusual cells strongly suggests that similar pathogenetic mechanisms may impact on the phenotype of H/RS cells in humans and mice.
###end p 33
###begin title 34
Impact of Transgene Integration
###end title 34
###begin p 35
###xml 335 344 335 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g005">Figure 5A</xref>
###xml 582 586 582 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Ito1">[12]</xref>
###xml 808 817 801 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g005">Figure 5B</xref>
###xml 1637 1646 1623 1632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g005">Figure 5C</xref>
###xml 1795 1804 1781 1790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008539-g005">Figure 5D</xref>
###xml 73 79 <span type="species:ncbi:10090">murine</span>
###xml 246 251 <span type="species:ncbi:10090">mouse</span>
###xml 290 295 <span type="species:ncbi:9606">human</span>
###xml 402 407 <span type="species:ncbi:10090">mouse</span>
###xml 557 563 <span type="species:ncbi:10090">murine</span>
###xml 1223 1228 <span type="species:ncbi:10090">mouse</span>
###xml 1461 1467 <span type="species:ncbi:10090">murine</span>
###xml 1592 1598 <span type="species:ncbi:10090">murine</span>
To determine whether transgene chromosomal integration disturbed a known murine locus with oncogenic or suppressor gene function, we sought to localize the exact insertion site. The chimeric class II genes were created by replacing exon 2 of the mouse gene with exon 2 of the corresponding human DR4 gene. The two chimeric constructs (Figure 5A), also comprising the locus control regions (LCR) of the mouse class II locus, were co-microinjected into C57BL/6 blastocysts. Therefore, the chimeric class II gene was expressed under the control of the natural murine class II promoter [12]. To determine the chromosomal integration site, we first performed fluorescence in-situ hybridization (FISH) using transgene-specific (DR4-exon2alpha and DR4-exon2beta) probes on splenocytes in metaphase. As indicated in Figure 5B, the avidin-Cy3.5-labeled probe (DR4-exon2alpha) showed a strong signal on both copies of chromosome 16 (comparable data for DR4-exon2beta not shown). The position of transgene integration was estimated on chromosome 16 to be near cytogenetic bands B3 to C2. The FISH analysis also revealed that integration of both the DR4-chimeric alpha and beta transgenes occurred together at a single location in the mouse genome. To further pinpoint the exact localization of this integration site, a genome walking analysis was performed using transgene specific primers combined with adaptor primers to "walk" from within the chimeric transgene to the murine chromosomal boundary region, yielding a fusion-sequence. This sequence contained DR4 transgene sequence at the 5'-end and a murine chromosome 16 sequence at the 3'-end (Figure 5C). The exact integration site was located by BLAST search of chromosome 16, at position +41138813 (Ensembl, ), corresponding to cytogenetic band B4 (Figure 5D). To date no known genes have been annotated in the vicinity of this chromosomal region based on alignment with Ensembl-Database.
###end p 35
###begin title 36
DR4-H2E constructs (DR4-a & DR4-b) and their genomic location after integration.
###end title 36
###begin p 37
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Ito1">[12]</xref>
###xml 173 178 <span type="species:ncbi:9606">human</span>
###xml 1031 1036 <span type="species:ncbi:10090">mouse</span>
(A) Schematic organization of the DR4-H2E constructs according to Ito et al. [12]. The endogenous exons 2 of DR4-H2Ea and DR4-H2Eb of the H2d-haplotype were replaced by the human exons 2 of HLA-DRA*0101 and HLA-DRB*0401, respectively in the described restriction enzyme sites of an SK+ vector. (B+C) Mapping of the DR4 transgene integration site. (B) left: Chromosomes from splenic metaphase; red circles mark the hybridization signals of a DR4-H2Ea-specific probe labeled with avidin-Cy3.5. Exemplary illustration of DR4-H2Ea in the genomic region between the cytogenetic banding B3 and C2, right: Diploid set of chromosomes arranged in a karyogramm. Both copies of chromosomes 16 show a hybridization signal (red circle) at the same genomic location. (C+D) Exact localization of transgene integration in Chromosome 16. (C) Fusion sequence of transgene integration. The 5' end starts with the transgenic sequence of a DR4-alpha-construct marked in the middle is the integration site followed by the endogenous sequence of the DR4 mouse strain. Sequence was analyzed by using the NCBI-BLAST-software () and determined at position +41138813 (Ensemble, ). (D) Schematic diagram of Chromosome 16. The integration was localized to cytogenetic band B4 by genome walking analysis.
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 739 743 739 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Deshpande1">[10]</xref>
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
###xml 158 163 <span type="species:ncbi:10090">mouse</span>
###xml 890 894 <span type="species:ncbi:10090">mice</span>
The development of diverse hematological malignancies in this DR4 transgenic mouse line represents a unique phenotype that has not been seen to date in other mouse tumor models. These animals spontaneously develop a variety of lymphoid malignancies in both the T and B cell lineages. Furthermore, the neoplasms represent different developmental stages of T cells (DP and SP T cells) and B cells (pre, pro, immature, mature, plasma cells). While the majority of malignancies were derived from the lymphoid lineage, the development of several cases of AML point towards the possibility that lymphoid, or even earlier precursor cells with lymphoid characteristics, occasionally transformed into myeloid tumors, as recently proposed by others [10]. Malignant transformation was strongly restricted to the hematopoietic lineage since only one case of carcinoma was observed in the more than 250 mice that underwent multi-organ histological examination. This probably reflects a high propensity for rapidly dividing hematopoietic cells to undergo malignant transformation.
###end p 39
###begin p 40
###xml 691 692 691 692 <monospace xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">.</monospace>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
The expression of only one transgenic chromosome 16 in heterozygous F1 mice was sufficient to allow development of similarly diverse neoplasms. Since only 70% of DR4 mice and 53% of F1 mice developed tumors, DR4-H2E transgene expression/integration alone was not sufficient for tumorigenesis. The observation that malignancy first appeared around eight months of age is consistent with a time-dependent, multi-step process of transformation in these mice. The primary hit may impact an early cell, perhaps a stem or early progenitor/precursor cell, since some myeloid malignancies were observed but the final events in tumorigenesis were only manifest at later stages of cellular development. A single transformation event, occurring in an early stem/precursor cell, seemed unlikely since this should lead to polyclonal tumors, whereas the vast majority of lymphomas were monoclonal with respect to TCR or IgH rearrangements. Nevertheless, the strong propensity for B and T cell lymphomas may be related to events occurring during Ig or TCR receptor rearrangement that contributed to a postulated accumulation of genetic hits needed for ultimate transformation. When tumors were first apparent they were very aggressive and caused fulminant and wide-spread disease, arguing against an early development of tumors that remained quiescent and unseen during the first months of life.
###end p 40
###begin p 41
###xml 325 329 325 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Bargou1">[26]</xref>
###xml 331 335 331 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Kapp1">[27]</xref>
###xml 337 341 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-vonKalle1">[28]</xref>
###xml 903 907 903 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Kanzler1">[23]</xref>
###xml 909 913 909 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Kuppers1">[24]</xref>
###xml 1083 1087 1083 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Brauninger1">[14]</xref>
###xml 1089 1093 1089 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Zettl1">[15]</xref>
###xml 1242 1243 1242 1243 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 1246 1247 1246 1247 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 1253 1254 1253 1254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 1383 1387 1383 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Caleo1">[29]</xref>
###xml 205 211 <span type="species:ncbi:10090">murine</span>
###xml 242 247 <span type="species:ncbi:9606">human</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
###xml 519 524 <span type="species:ncbi:9606">human</span>
###xml 886 891 <span type="species:ncbi:9606">human</span>
###xml 923 928 <span type="species:ncbi:9606">human</span>
###xml 1210 1214 <span type="species:ncbi:10090">mice</span>
###xml 1316 1321 <span type="species:ncbi:9606">human</span>
###xml 1560 1566 <span type="species:ncbi:10090">murine</span>
###xml 1813 1819 <span type="species:ncbi:10090">murine</span>
Among the diverse malignancies, the appearance of H-like and R/S-like cells in the compartment of T cell/histiocytic-rich DLBCL is of particular interest. Various investigators have attempted to establish murine models of HL by transplanting human HL cell lines or freshly isolated HL biopsies into immunodeficient SCID mice [26], [27], [28]. These models are limited by their xenogeneic nature, whereas the DR4 mice described here provide cases of spontaneous disease with morphological and phenotypic similarities to human T cell/histiocyte rich DLBCL and HL with characteristic H/RS-like cells. Single cell analysis of IgH-rearrangements in the H/RS-like cells revealed a B cell origin in four of five examined cases. Furthermore, "crippled" mutations in the hypervariable CDR3-regions suggested a pre-apoptotic germinal center B cell origin in at least two cases, as shown for some human H/RS cells [23], [24]. In most human composite lymphomas, a shared precursor for the HL and accompanying B cell tumor was demonstrated by presence of common Ig sequences and shared mutations [14], [15]. In contrast, sequence comparisons of the microdissected HL-like cells and the accompanying DLBCL-HA or SMZL in DR4 mice showed clonally unrelated VH, DH and JH-families. Likewise, the group of Caleo described a composite human HL and mantle cell lymphoma as two clonally unrelated tumors [29]. Furthermore, comparison of IgH sequences with germline configurations revealed accumulation of mutations in framework (FR1-FR3) and complementarity-regions (CDR1-CDR3) of murine H/RS-like cells that were not detected in accompanying DLBCL-HA or SMZL (data not shown), revealing their origin from two distinct B cells. Nevertheless, the appearance of additional mutations outside the CDR3-region supports the conclusion that murine H/RS-like cells were derived from GC B cells and the crippled mutations seen in two cases were the result of ongoing somatic mutations rather than being due to aberrant VDJ recombination.
###end p 41
###begin p 42
###xml 420 424 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Ito1">[12]</xref>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 173 177 <span type="species:ncbi:10090">mice</span>
###xml 192 198 <span type="species:ncbi:10090">murine</span>
The cellular and molecular analyses of the DR4 mice provide substantial insight into the basis of tumor development. The genomic DR4-H2E transgenes used for creation of DR4 mice contained the murine class II promoter and locus control regions (LCR), enabling natural expression of the chimeric proteins in the appropriate cells and at the appropriate stages of development, as expected for a normal H2 class II molecule [12]. Thereby, the DR4-H2E transgene was not aberrantly expressed in time or place in a manner that could contribute to tumor development.
###end p 42
###begin p 43
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Grusby1">[30]</xref>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Sonderstrup1">[31]</xref>
###xml 298 302 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
###xml 688 692 <span type="species:ncbi:10090">mice</span>
###xml 1157 1161 <span type="species:ncbi:10090">mice</span>
###xml 1286 1290 <span type="species:ncbi:10090">mice</span>
It cannot be ascertained whether the chimeric class II protein plays a direct role in lymphoma development since only one founder line was retained by the original investigators and is available for study today. To the best of our knowledge this type of lymphoma development is unique to these DR4 mice since a literature search did not reveal a similar phenotype in other MHC class II tg mice [30], [31]. However, long periods of observation may be needed to detect tumors. If the DR4-H2E chimeric protein is directly involved, its expression alone is not sufficient for tumor development because only 70% of homozygous DR4 mice developed tumors, as ascertained by monitoring of all DR4 mice throughout their entire natural lifespan. It remains to be determined whether the chimeric class II protein impinges on particular cellular interactions or functions that could contribute to malignant transformation. It should be noted that chimeric protein expression in tumor cells was not essential, since the T cell tumors were all class II negative (data not shown). H2 class II deficiency appeared not to be essential for tumorigenesis since heterogenous F1 mice were also affected, despite carrying one normal H2 haplotype. Since the frequency of tumors was lower in F1 compared to DR4 mice, further studies are required to determine if there is some subtle impact of H2 class II deficiency on tumor development.
###end p 43
###begin p 44
###xml 87 93 <span type="species:ncbi:10090">murine</span>
At first, it seemed most plausible that transgene insertion impacted on one or several murine loci, causing oncogenic effects. The finding that integration of both constructs occurred at a single site ruled out multiple hits due to multiple transgene insertion sites. Furthermore, identification of the exact transgene integration site failed to reveal disruption of a known suppressor gene or activation of a potential oncogene since no annotated gene is located within 1 MB in both directions of the insertion site. However, it is possible that long-range effects on other loci, aberrant recombination events, or abnormal chromosomal pairing and segregation caused by transgene integration could contribute to tumorigenesis. It is also possible that impacts on non-coding sequences localized near the integration site could play a role in tumor development. The age-related appearance of tumors suggests a multi-step process. Future broad scale approaches, therefore, will be needed to further pinpoint the complex mechanisms contributing to lymphoma development.
###end p 44
###begin p 45
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Ward1">[32]</xref>
###xml 562 563 562 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 194 198 <span type="species:ncbi:10090">mice</span>
###xml 234 237 <span type="species:ncbi:9606">man</span>
###xml 302 306 <span type="species:ncbi:10090">mice</span>
###xml 347 352 <span type="species:ncbi:9606">human</span>
###xml 666 671 <span type="species:ncbi:10090">mouse</span>
###xml 682 687 <span type="species:ncbi:9606">human</span>
###xml 893 898 <span type="species:ncbi:9606">human</span>
###xml 1073 1076 <span type="species:ncbi:9606">man</span>
In summary, this DR4 line is a unique lymphoma "generator" that yields diverse hematological malignancies. The majority of lymphomas, including the DP LTCL, SMZL and DLBCL-HA described in these mice, represent significant diseases in man, whereas most other naturally occurring hematological tumors in mice do not share major characteristics with human tumors [32]. The appearance of several cases of AML opens the door to better elucidate the origin of these leukemias in relation to lymphoid malignancies. Furthermore, the identification of neoplasms with CD30+ H/RS-like cells with a probable origin from GC B cells may contribute to development of a long-sought mouse model for human HL. Current xenogeneic models of HL are hampered by low engraftment efficiency and the need for immune suppression. In addition, these transplanted cells lack the characteristic morphological phenotype of human HL. Therefore, a number of features of the DR4 line make it a useful model to investigate common molecular mechanisms that may contribute to important neoplastic diseases in man. Based on the high frequency of spontaneous tumor development, this DR4 line can also be used to assess targeted therapies with potential for wide application in different hematopoietic malignancies.
###end p 45
###begin title 46
Material and Methods
###end title 46
###begin title 47
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 47
###begin p 48
###xml 38 42 38 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Ito1">[12]</xref>
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 94 98 <span type="species:ncbi:10090">Mice</span>
###xml 146 151 <span type="species:ncbi:10090">Mouse</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 295 299 <span type="species:ncbi:10090">mice</span>
DR4 tg mice have a C57BL/6 background [12] and were a kind gift of Z. Nagy (Munich, Germany). Mice were bred and propagated under SPF conditions. Mouse studies were conducted according to German law by approved experimental protocols. C57BL/6 mice (Taconic) were crossed with DR4 to generate F1 mice. At first sign of disease, animals were euthanized and dissected organs prepared for histopathology, immunohistochemistry (formalin-fixed/paraffin-embedded or cryopreserved) and flow cytometry (single cell suspensions).
###end p 48
###begin title 49
Classification
###end title 49
###begin p 50
###xml 91 94 91 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Kogan1">[1]</xref>
###xml 96 99 96 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Morse1">[2]</xref>
The classification of lymphoid and non-lymphoid tumors was based on the Bethesda Proposals [1], [2] and was supported by parallel flow cytometry studies. More information is provided in supplementary data.
###end p 50
###begin title 51
Histopathology/Immunohistochemistry (IHC)
###end title 51
###begin p 52
###xml 220 224 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Kunder1">[21]</xref>
###xml 489 493 <span type="species:ncbi:9925">goat</span>
###xml 499 504 <span type="species:ncbi:10090">mouse</span>
###xml 515 519 <span type="species:ncbi:9925">goat</span>
###xml 525 531 <span type="species:ncbi:9986">rabbit</span>
Formalin-fixed lymph nodes, spleen and other organs were embedded in paraffin, cut in 2-3 microm sections and stained with H&E. Automated immunohistochemical staining (Ventana Medical Systems) was performed as published [21] using the following primary antibodies: CD45R/B220 (BD), CD3, CD79a, Tdt (Dako), CD30 (Chemicon), CD49b (eBioscience), MPO (NeoMarkers). The L243 (HLA-DR) antibody was kindly provided by J.P. Johnson (Ludwig-Maximilians-Universitat, Munich, Germany). Biotinylated goat anti-mouse (Dako) or goat anti-rabbit (Vector) IgG antibodies were used as secondary reagents, linked to a streptavidin-HRP-complex (Jackson Immunoresearch Laboratories) and visualized with diaminobenzidine (Sigma-Aldrich).
###end p 52
###begin title 53
Laser-Assisted Microdissection of Single Cells
###end title 53
###begin p 54
Cryosections (12 microm) were transferred onto PEN-PALM membrane slides (P.A.L.M.) and stained with H&E. Microdissection was performed in areas containing one H/RS cell. Up to 8-10 H/RS-like cells per sample were transferred into PALM Adhesive Caps (P.A.L.M.) using the P.A.L.M MicroBeam instrument. The mRNA was isolated with the BioNobile Quick Pick mRNA-Isolation Kit (BioNobile) according to the manufacturer's protocol and further processed with the message Booster cDNA Synthesis Kit for qPCR (Epicentre).
###end p 54
###begin title 55
RNA
###end title 55
###begin p 56
###xml 222 225 <span type="species:ncbi:11866?0.5863095238095238|species:ncbi:12321?0.21726190476190477">AMV</span>
RNA isolation of single cell suspensions or 20 microm thick tissue-cryosections was performed using the RNeasy-Kit (QIAGEN) following the manufacturer's protocol. Total RNA (1 microg) was reverse transcribed utilizing the AMV-First Strand cDNA-Synthesis Kit (Roche).
###end p 56
###begin title 57
Clonality Analysis of B Cells
###end title 57
###begin p 58
###xml 134 138 134 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Plus</sup>
###xml 181 218 181 218 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGGTC/GA/CAA/GCTGCAGC/GAGTCATGG-3&#8242;</named-content>
###xml 235 272 235 272 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;TGAGGAGACGGTGACCGTGGTCCCTTGGCCCC-3&#8242;</named-content>
###xml 382 383 382 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 419 420 419 420 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</sub>
###xml 930 934 894 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Lefranc1">[22]</xref>
###xml 936 940 900 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Giudicelli1">[33]</xref>
Amplification of IgH rearrangements was performed by RT-PCR on a LightCycler (LC) instrument (Roche) using the LC FastStart DNA MasterPlus SYBR Green I-Kit. Degenerated IgH forward 5'-AGGTC/GA/CAA/GCTGCAGC/GAGTCATGG-3' and IgH reverse 5'TGAGGAGACGGTGACCGTGGTCCCTTGGCCCC-3' were kindly provided by R. Mocikat (Helmholtz Zentrum Munchen, Germany). The forward primer annealed to the VH-region, the reverse primer to the JH-region and yielded products of approximately330 bp that included the VDJ-junction. LC-PCR conditions used initial denaturation at 95degreesC for 10 min followed by 35 cycles at 95degreesC for 0 sec, annealing at 65degreesC for 25 sec and elongation at 72degreesC for 25 sec. Specific fragments were extracted with NucleoSpin Extract II-Kit (Macherey&Nagel) and sequenced (Sequiserve) afterwards. Obtained sequences were compared with germline configurations using IMGT/V-Quest software on the IMGT website () [22], [33].
###end p 58
###begin title 59
Clonality Analysis of T Cells
###end title 59
###begin p 60
###xml 178 182 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Pannetier1">[17]</xref>
###xml 235 303 226 294 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCGGCTTGGGTGGAGTCACATTTCTC-3&#8242;</named-content>
###xml 608 609 587 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 638 639 617 618 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
TCR-Vbeta-repertoire analysis was performed by RT-PCR on a Speed-Cycler instrument (Analytik-Jena) using a 5' forward primer panel (21 Vbeta-family primers) described previously [17]. The reverse TCR-Jbeta primer containing a GC-clamp 5'-CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCGGCTTGGGTGGAGTCACATTTCTC-3' was kindly provided by R. Mocikat. In each PCR, 22 single reaction mixes were set up in a special 36-well-plate (Analytik-Jena). The volume of each single mix was 20 microL and contained all components except the primer (each 2.5 pmol) with 0.9 microL cDNA, 2 microL 10x buffer, 0.2 mM dNTPs, 0.5 mM MgCl2, 1 unit Taq polymerase and H2O. PCR conditions used initial denaturation at 94degreesC 2 min, followed by 40 cycles of denaturation at 94degreesC for 15 sec, annealing at 60degreesC for 25 sec, elongation at 72degreesC for 30 sec and a final elongation of 72degreesC for 5 min. Editable sequences were compared with germline configurations using IMGT/V-Quest software.
###end p 60
###begin title 61
Flow Cytometry Analysis of TCR-Vbeta-Repertoires
###end title 61
###begin p 62
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
TCR-Vbeta surface expression was analyzed using a mouse Vbeta TCR Screening Panel Antibody Kit including 15 monoclonal FITC-labeled antibodies (BD) as well as PE-labeled antibodies for Vbeta8.1/8.2 and Vbeta7, CD3-PacBlue, CD4-AlexaFl700, CD8-APC-Cy7, B220-PerCp-Cy5.5 (eBioscience). Staining was performed in the presence of Fc-receptor blocking antibody (clone 2.4G8 kind gift of E. Kremmer, Helmholtz Zentrum Munchen). All cells were processed on a LSRII Flow Cytometer (BD) and analyzed with FlowJo8.7.1 software. Dead cells were excluded using propidium iodide labeling and duplets by gating on single cells.
###end p 62
###begin title 63
Confocal Microscopy
###end title 63
###begin p 64
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Agard1">[34]</xref>
Cells were prepared as described for flow cytometry. Images were acquired on a Personal Deltavision Microscope (Applied Precision LLC). Image deconvolution was performed with a constrained iterative algorithm as described [34] and analyzed with SoftWoRx Suite software.
###end p 64
###begin title 65
FISH Analysis
###end title 65
###begin p 66
###xml 83 87 83 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Akeson1">[35]</xref>
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008539-Henegariu1">[36]</xref>
###xml 206 233 202 229 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGAAGCAGGGGGACTATGAC-3&#8242;</named-content>
###xml 254 283 250 279 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CATTGGTGATCGGAGTATAGTTG-3&#8242;</named-content>
###xml 142 147 <span type="species:ncbi:9606">human</span>
FISH analysis was performed on chromosome metaphase spreads as described elsewhere [35], [36]. Probes for FISH analysis were specific for the human exon-2 sequence and were amplified with hEx2alpha forward 5'-GGGAAGCAGGGGGACTATGAC-3' and reverse primers 5'-CATTGGTGATCGGAGTATAGTTG-3' labeled with a Biochem-link kit from Roche followed by hybridization to chromosomal metaphase spreads of DR4 splenocytes. The transgenic chromosome(s) positive for DR4-H2Ealpha were tentatively identified by size and DAPI banding. Images were recorded with a motorized Zeiss Axioplan Imaging II microscope (Zeiss, Gottingen, Germany) and the Isis/V3.4.0-Software (Metasystems, Altlussheim, Germany).
###end p 66
###begin title 67
Genome Walking
###end title 67
###begin p 68
###xml 245 278 237 270 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGAGACCTCATCTTCTTCAGTTTCCAG-3&#8242;</named-content>
###xml 293 344 281 332 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTAATACGACTCACTCACTATAGGGCACTATAGGGCACGCGTGGT-3&#8242;</named-content>
###xml 375 408 359 392 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTTTTTGTGCCTGAGCCAGTTCTTGGT-3&#8242;</named-content>
###xml 423 448 403 428 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ACTATAGGGCACGCGTGGT-3&#8242;</named-content>
Genome walking analysis was performed with the GenomeWalker Universal kit (BD Biosciences Clontech) according to the user's manual. Gene-specific primer (GSP) and adaptor primer (AP) for the DR4-H2Ealpha-construct were used as follows alphaGSP1 5'-GGAGACCTCATCTTCTTCAGTTTCCAG-3', and alphaAP1 5'-GTAATACGACTCACTCACTATAGGGCACTATAGGGCACGCGTGGT-3' for primary PCR and alphaGSP2 5'-GTTTTTGTGCCTGAGCCAGTTCTTGGT-3', and alphaAP2 5'-ACTATAGGGCACGCGTGGT-3' for secondary PCR.
###end p 68
###begin title 69
Accession Numbers
###end title 69
###begin p 70
Sequence data of lymphoid receptors with the following accession numbers FM179543-FM179580, FM179582-FM179603 and FM179714-FM179741 can be accessed from EMBL Nucleotide Sequence Database.
###end p 70
###begin title 71
Supporting Information
###end title 71
###begin p 72
###xml 338 339 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Histological and immunohistological staining of composite and non-lymphoid tumors. (A-H) Composite tumors consisted of different types of lymphoid tumors (A-E) or a B cell tumor was associated with an AML (F-H). (A-D) The LTCL in thymus and lymph nodes (left side) is accompanied by a DLBCL in the spleen (right side). (C) The LTCL is CD3+ and (D) the DLBCL is positive for CD79a. (E) Both composite tumors in the spleen are of B-cellular origin: The DLBCL-HA on the left side can be distinguished from the splenic marginal zone lymphoma (SMZL) on the right side. (F-H) A composite tumor in the spleen, which consists of (G) a B220-positive diffuse large B cell lymphoma (DLBCL), and (H) an MPO-positive acute myeloid leukemia (AML). (I-L) The well-differentiated acute myeloid leukemia (AML) with maturation consists of myeloblasts (less than 90%) and mature granulocytes with typical doughnut-like shape. (I) H&E stained section, (J) Immunohistochemically, it is characterized by myeloperoxidase (MPO) positivity of the mature granulocytes, (K) B220- and (L) CD3- cells. (M) Histiocytic sarcoma in lymph node section. All bars equal 50 microm.
###end p 72
###begin p 73
(1.41 MB TIF)
###end p 73
###begin p 74
Click here for additional data file.
###end p 74
###begin p 75
###xml 24 28 <span type="species:ncbi:10090">mice</span>
T cell neoplasms in DR4 mice. Phenotypes of T cell tumors and their monoclonal TCRVbetaeta chain sequences (CDR3-region).
###end p 75
###begin p 76
(0.37 MB TIF)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
###xml 23 27 <span type="species:ncbi:10090">mice</span>
T cell neoplasms in F1 mice. Phenotypes of T cell tumors and their monoclonal TCRVbetaeta chain sequences (CDR3-region).
###end p 78
###begin p 79
(0.27 MB TIF)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin p 81
###xml 24 28 <span type="species:ncbi:10090">mice</span>
B cell neoplasms in DR4 mice. Phenotypes of B cell tumors and their rearranged IgH-V family sequences (CDR3-region).
###end p 81
###begin p 82
(0.38 MB TIF)
###end p 82
###begin p 83
Click here for additional data file.
###end p 83
###begin p 84
###xml 23 27 <span type="species:ncbi:10090">mice</span>
B cell neoplasms in F1 mice (no FACS data). Rearranged IgH-V family sequences (CDR3-region).
###end p 84
###begin p 85
(0.14 MB TIF)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin p 87
###xml 22 26 <span type="species:ncbi:10090">mice</span>
HL-like tumors in DR4 mice (microdissected pooled single cells). Rearranged IgH-V family sequences (CDR3-region).
###end p 87
###begin p 88
(0.11 MB TIF)
###end p 88
###begin p 89
Click here for additional data file.
###end p 89
###begin p 90
###xml 24 28 <span type="species:ncbi:10090">mice</span>
Composite tumors in DR4 mice (whole spleen samples). Rearranged IgH-V family sequences (CDR3-region).
###end p 90
###begin p 91
(0.13 MB TIF)
###end p 91
###begin p 92
Click here for additional data file.
###end p 92
###begin p 93
Immunhistology and flow cytometry of B cell lymphomas.
###end p 93
###begin p 94
(0.36 MB TIF)
###end p 94
###begin p 95
Click here for additional data file.
###end p 95
###begin p 96
Flow cytometric classification of tumors Cell staining was performed in the presence of Fc-receptor blocking antibody (clone 2.4G8, kind gift of E. Kremmer, Helmholtz Zentrum Munchen) using the following antibodies: FITC-labeled anti-CD62L, -TCRba, -CD4, -IgD, -2.4G2, PE-labeled anti-TCRdg, -CD117 (ckit), -CD11c, -CD70, -CD122, -CD86, APC-labeled anti-CD44, -IgM, -CD49b, L243 (HLA-DR), APC-Cy7-labeled anti-CD19, anti-GR1, -CD8, PE-Cy7-labeled anti-CD25, anti-CD11b CD4-Ax700, B220-PerCpCy5.5, CD3-Pacific Blue. Flow cytometry analysis was performed on a LSRII Flow Cytometer (BD) and analyzed with FlowJo8.7.1-software. Dead cells were excluded using propidium iodide labeling and duplets by gating on single cells (FSC-H to FSC-A channel).
###end p 96
###begin p 97
(0.03 MB DOC)
###end p 97
###begin p 98
Click here for additional data file.
###end p 98
###begin p 99
###xml 203 207 <span type="species:ncbi:10090">mice</span>
We thank members of the Helmholtz Zentrum Munchen - Institute of Pathology (J. Muller, C. Kloss, N. Kink and E. Samson) for assistance with histopathology and the Animal Facility for breeding DR4 and F1 mice. M. Speicher, J. Geigl and I. Jentsch (Technical University Munich, Germany) for assistance with FISH-Analysis, H. Ostermann (Chromaphor) for assistance with confocal microscopy and F. Beyschlag for assistance with lymphoid receptor analysis. We thank E. Simpson (Imperial College, London, GB) and R. Mocikat (Helmholtz Zentrum Munchen, Munich, Germany) for critical reading of the manuscript.
###end p 99
###begin title 100
References
###end title 100
###begin article-title 101
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.
###end article-title 101
###begin article-title 102
###xml 63 67 <span type="species:ncbi:10090">mice</span>
Bethesda proposals for classification of lymphoid neoplasms in mice.
###end article-title 102
###begin article-title 103
Myc translocations in B cell and plasma cell neoplasms.
###end article-title 103
###begin article-title 104
The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.
###end article-title 104
###begin article-title 105
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
Nucleotide excision repair- and p53-deficient mouse models in cancer research.
###end article-title 105
###begin article-title 106
###xml 62 68 <span type="species:ncbi:10090">murine</span>
Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma.
###end article-title 106
###begin article-title 107
###xml 96 111 <span type="species:ncbi:10090">transgenic mice</span>
Proviral activation of the tumor suppressor E2a contributes to T cell lymphomagenesis in EmuMyc transgenic mice.
###end article-title 107
###begin article-title 108
###xml 40 45 <span type="species:ncbi:10090">mouse</span>
Establishment and characterization of a mouse strain (TLL) that spontaneously develops T-cell lymphomas/leukemia.
###end article-title 108
###begin article-title 109
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
###end article-title 109
###begin article-title 110
Lymphoid progenitors as candidate cancer stem cells in AML: new perspectives.
###end article-title 110
###begin article-title 111
###xml 82 86 <span type="species:ncbi:11786">MuLV</span>
Genetic heterogeneity in acute myeloid leukemia: maximizing information flow from MuLV mutagenesis studies.
###end article-title 111
###begin article-title 112
###xml 41 47 <span type="species:ncbi:10090">murine</span>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis.
###end article-title 112
###begin article-title 113
Immunoglobulin gene rearrangement analysis in composite hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells?
###end article-title 113
###begin article-title 114
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma.
###end article-title 114
###begin article-title 115
Composite marginal zone B-cell lymphoma and classical Hodgkin's lymphoma: a clinicopathological study of 12 cases.
###end article-title 115
###begin article-title 116
Precursor T lymphoblastic leukaemia/lymphoblastic lymphoma (precursor T-cell acute lymphoblastic leukaemia).
###end article-title 116
###begin article-title 117
###xml 51 57 <span type="species:ncbi:10090">murine</span>
The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments.
###end article-title 117
###begin article-title 118
Normal T lymphocytes can express two different T cell receptor beta chains: implications for the mechanism of allelic exclusion.
###end article-title 118
###begin article-title 119
###xml 57 72 <span type="species:ncbi:10090">transgenic mice</span>
T cells with dual antigen specificity in T cell receptor transgenic mice rejecting allografts.
###end article-title 119
###begin article-title 120
T-cell/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells.
###end article-title 120
###begin article-title 121
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 146 151 <span type="species:ncbi:10090">mouse</span>
###xml 165 170 <span type="species:ncbi:9606">human</span>
###xml 202 208 <span type="species:ncbi:10090">murine</span>
A comprehensive antibody panel for immunohistochemical analysis of formalin-fixed, paraffin-embedded hematopoietic neoplasms of mice: analysis of mouse specific and human antibodies cross-reactive with murine tissue.
###end article-title 121
###begin article-title 122
IMGT, the international ImMunoGeneTics database.
###end article-title 122
###begin article-title 123
Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.
###end article-title 123
###begin article-title 124
Single cell analysis of Hodgkin/Reed-Sternberg cells.
###end article-title 124
###begin article-title 125
Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
###end article-title 125
###begin article-title 126
###xml 147 151 <span type="species:ncbi:10090">mice</span>
Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice.
###end article-title 126
###begin article-title 127
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Hodgkin's lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice.
###end article-title 127
###begin article-title 128
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Growth of Hodgkin cell lines in severely combined immunodeficient mice.
###end article-title 128
###begin article-title 129
Composite Hodgkin lymphoma and mantle cell lymphoma: two clonally unrelated tumors.
###end article-title 129
###begin article-title 130
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Immune responses in MHC class II-deficient mice.
###end article-title 130
###begin article-title 131
###xml 13 28 <span type="species:ncbi:10090">transgenic mice</span>
###xml 44 49 <span type="species:ncbi:9606">human</span>
HLA class II transgenic mice: models of the human CD4+ T-cell immune response.
###end article-title 131
###begin article-title 132
###xml 27 31 <span type="species:ncbi:10090">mice</span>
Lymphomas and leukemias in mice.
###end article-title 132
###begin article-title 133
IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis.
###end article-title 133
###begin article-title 134
Fluorescence microscopy in three dimensions.
###end article-title 134
###begin article-title 135
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
Mitotic chromosome preparations from mouse cells for karyotyping.
###end article-title 135
###begin article-title 136
Improvements in cytogenetic slide preparation: controlled chromosome spreading, chemical aging and gradual denaturing.
###end article-title 136
###begin p 137
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 137
###begin p 138
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was partially supported by the Federal Ministry of Education and Research (NGFN2), the Helmholtz Society (Alliance for Immunotherapy of Cancer, HA-202) and the German Research Foundation (SFB-TR36). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 138

